Such an important topic and I have come across this recent resource: https://www.cdc.gov/diabetes/professional-info/health-care-pro/diabetes-pharmacy-health.html
I have not utilized personally in my public health work, but can be useful in analyzing big data. I found this interesting for potential application: https://blogs.cdc.gov/genomics/2022/03/01/artificial-intelligence-2/
Still so new with concerns ethically and regulatory
"Experts say this variant has a higher transmissibility rate than previous strains but doesn't appear to be more dangerous." At least good news on the danger level.
There was a decrease in antibiotic use specifically for pneumonia, but due to the 1-day seminar, could there be potential underutilization for a period after? However,
"Our data demonstrate that the implementation of an ASP was associated with a reduction in the use of broad-spectrum antibiotics and macrolides and increased guideline adherence for the safe treatment of CAP."
Seems to be consistent across other studies in different areas.
"ASPs are a key strategy in tackling the emerging threat of AMR and have a positive impact on antibiotic consumption and resistance."
You would hope there would be a difference in antibiotic use, but if it was needed for patients, then incentives may not matter.
"did not observe meaningful changes in total antibiotic use between the incentivized and unincentivized hospitals for ASP teams."
Webinar